IanFromSI
13 minutes ago
Revance Therapeutics (RVNC) generated significant revenue from both Daxxify and its partnership with Teoxane’s RHA product line in 2024. In Q2 2024, revenue from Daxxify, primarily in the aesthetics segment, grew by 27% year-over-year, reaching $28.7 million. Additionally, the RHA Collection, which